Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

By adminFebruary 11, 2024Global News Feed

LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced today the closing of its previously announced underwritten public offering of 5,535,055 shares of its common stock. Each share of common stock was sold at a price to the public of $2.71 per share. The gross proceeds to ImmixBio from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ImmixBio. The Company intends to use the net proceeds from this offering for NXC-201 clinical trials, working capital and general corporate purposes.

More here:
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Telomir Pharmaceuticals Announces Pricing of Initial Public Offering

By adminFebruary 11, 2024Global News Feed

BALTIMORE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, is developing Telomir-1 as the first novel small molecule, to lengthen the DNA’s protective telomere caps in order to affect age reversal, today announced the pricing of its initial public offering of 1,000,000 shares of its common stock at a public offering price of $7.00 per share. All of the shares of common stock are being offered by Telomir. In addition, Telomir has granted the underwriters a 45-day option to purchase up to an additional 150,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Capital Market on February 9, 2024 under the ticker symbol "TELO." The gross proceeds to Telomir from the initial public offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $7 million. The initial public offering is expected to close on February 13, 2024, subject to satisfaction of customary closing conditions.

See the original post here:
Telomir Pharmaceuticals Announces Pricing of Initial Public Offering

Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

By adminFebruary 11, 2024Global News Feed

AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.?(Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.

Visit link:
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Metagenomi Announces Pricing of Initial Public Offering

By adminFebruary 11, 2024Global News Feed

EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (“Metagenomi”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a price to the public of $15.00 per share. The gross proceeds to Metagenomi from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $93,750,000. All of the shares are being offered by Metagenomi. In addition, Metagenomi has granted the underwriters a 30-day option to buy an additional 937,500 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

The rest is here:
Metagenomi Announces Pricing of Initial Public Offering

Invitation to presentation of Mendus’ year-end report for 2023

By adminFebruary 11, 2024Global News Feed

Mendus AB (“Mendus” publ; IMMU.ST), will publish its year-end report for 2023 on Wednesday 14 February 2024 at 08:00 CET. The company will hold a conference call and an online presentation on the same day at 10:00 CET. The call will be hosted by CEO Erik Manting. The presentation will be in English and followed by a question-and-answer session.

Read this article:
Invitation to presentation of Mendus’ year-end report for 2023

Invitation to an extraordinary shareholders’ meeting of Novozymes A/S

By adminFebruary 11, 2024Global News Feed

An extraordinary shareholders’ meeting of Novozymes A/S will be held on Monday March 4, 2024 at 4:00 pm CET at Boege Alle 10-12, 2970 Hoersholm, Denmark.

Read more:
Invitation to an extraordinary shareholders’ meeting of Novozymes A/S

Vistin Pharma ASA: Invitation to Q4 2023 conference call

By adminFebruary 11, 2024Global News Feed

Oslo, Norway, 9 February 2024

Read the original post:
Vistin Pharma ASA: Invitation to Q4 2023 conference call

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with…

By adminFebruary 11, 2024Global News Feed

- Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference -

Visit link:
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with...

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

By adminFebruary 11, 2024Global News Feed

LONDON and NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared OK-101 as its first Investigational New Drug (IND) application for the treatment of NCP.

Read the original here:
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC…

By adminFebruary 11, 2024Global News Feed

BOSTON & LONDON, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced that data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia, will be presented during an oral presentation at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Frankfurt, Germany, today, February 9, 2024. The Company previously shared Part 5 results during a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.

See the rest here:
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC...